Patents by Inventor Laura Beth Johnson McIntire

Laura Beth Johnson McIntire has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods of reducing levels of tau
    Patent number: 9696306
    Abstract: Successful CNS drug discovery requires a scalable, highly physiological neuronal model. Using directed differentiation of mouse embryonic stem (mES) cells, including mES cells isolated from a mouse model of Alzheimer's disease (AD), a highly homogeneous primary neuronal model amenable to phenotypic assays for production and synaptotoxicity of amyloid ?-peptide was developed. This model furnishes a highly physiological and AD-relevant platform suitable for high throughput small molecule and functional genetic screens, providing specific small molecule compounds identified by such screens.
    Type: Grant
    Filed: September 6, 2013
    Date of Patent: July 4, 2017
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: Tae-Wan Kim, Laura Beth Johnson McIntire, Natalie Landman, Gina Finan
  • Screening Assays Using Stem Cells and Stem Cell-Derived Neurons from Mouse Models of Alzheimer's Disease
    Publication number: 20140171380
    Abstract: Successful CNS drug discovery requires a scalable, highly physiological neuronal model. Using directed differentiation of mouse embryonic stem (mES) cells, including mES cells isolated from a mouse model of Alzheimer's disease (AD), a highly homogeneous primary neuronal model amenable to phenotypic assays for production and synaptotoxicity of amyloid ?-peptide was developed. This model furnishes a highly physiological and AD-relevant platform suitable for high throughput small molecule and functional genetic screens, providing specific small molecule compounds identified by such screens.
    Type: Application
    Filed: September 6, 2013
    Publication date: June 19, 2014
    Applicant: The Trustees of Columbia University in the City of New York
    Inventors: Tae-Wan Kim, Laura Beth Johnson McIntire, Natalie Landman, Gina Finan
  • Phosphoinositide modulation for the treatment of neurodegenerative diseases
    Patent number: 8288378
    Abstract: The present invention relates to the use of agents that inhibit the toxic effects of amyloid oligomers by increasing intracellular levels of phosphoinositol 4-phosphate (PI(4)P, or “PIP”) and/or phosphotidylinositol 4,5-biphosphate (PI(4,5)P2 or “PIP2”), the use of such agents for the treatment of neurodegenerative diseases, methods of treating neurodegenerative diseases by administration of agents which alter lipid metabolism, and methods of identifying agents which alter the association of presenilins with ?-secretase and lipid rafts.
    Type: Grant
    Filed: May 18, 2009
    Date of Patent: October 16, 2012
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: Tae-Wan Kim, Gilbert Di Paolo, Min Suk Kang, Diego Berman, Laura Beth Johnson McIntire
  • Phosphoinositide Modulation For The Treatment Of Neurodegenerative Diseases
    Publication number: 20100035811
    Abstract: The present invention relates to the use of agents that inhibit the toxic effects of amyloid oligomers by increasing intracellular levels of phosphoinositol 4-phosphate (PI(4)P, or “PIP”) and/or phosphotidylinositol 4,5-biphosphate (PI(4,5)P2 or “PIP2”), the use of such agents for the treatment of neurodegenerative diseases, methods of treating neurodegenerative diseases by administration of agents which alter lipid metabolism, and methods of identifying agents which alter the association of presenilins with ?-secretase and lipid rafts.
    Type: Application
    Filed: May 18, 2009
    Publication date: February 11, 2010
    Inventors: Tae-Wan Kim, Gilbert DiPaolo, Min Suk Kang, Diego Ezequiel Berman, Laura Beth Johnson McIntire